Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Short Interest Update

Serina Therapeutics, Inc. (NYSEAMERICAN:SER – Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 145,548 shares, a decline of 34.7% from the July 30th total of 222,920 shares. Based on an average daily volume of 69,205 shares, the short-interest ratio is currently 2.1 days. Approximately 0.7% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, BTIG Research assumed coverage on Serina Therapeutics in a research report on Wednesday, July 1st. They issued a “buy” rating and a $8.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $8.00.

Get Serina Therapeutics alerts:

Read Our Latest Report on SER

Serina Therapeutics Stock Performance

Shares of Serina Therapeutics stock opened at $2.62 on Thursday. The firm has a fifty day moving average of $2.28 and a two-hundred day moving average of $2.02. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.65 and a current ratio of 6.65. The stock has a market capitalization of $66.55 million, a price-to-earnings ratio of -1.39 and a beta of 1.18. Serina Therapeutics has a 52 week low of $1.22 and a 52 week high of $5.83.

Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter.

About Serina Therapeutics

(Get Free Report)

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.

See Also

• Five stocks we like better than Serina Therapeutics
• Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
• J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
• Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
• GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test

Receive News & Ratings for Serina Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Serina Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.